3 3. Greinix HT, Loddenkemper C, Pavletic SZ, et al. Diagnosis and staging of chronic graft‐versus‐host disease in the clinical practice. Biol Blood Marrow Transplant. 2011; 17:167–175.
4 4. Zeiser R, Blazar BR. Pathophysiology of chronic graft‐versus‐host disease and therapeutic targets. N Engl J Med. 2017; 377:2565–2579.
5 5. Cooke KR, Luznik L, Sarantopoulos S, et al. The Biology of Chronic Graft‐versus‐Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft‐versus‐Host Disease. Biol Blood Marrow Transplant. 2017; 23:211–234.
6 6. Blazar BR, Murphy WJ, Abedi M. Advances in graft‐versus‐host disease biology and therapy. Nat Rev Immunol. 2012; 12:443–458.
7 7. Welniak LA, Blazar BR, Murphy WJ. Immunobiology of allogeneic hematopoietic stem cell transplantation. Ann Rev Immunol. 2007; 25:139–170.
8 8. Gea‐Banacloche J, Komanduri KV, Carpenter P, et al. National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Immune Dysregulation and Pathobiology Working Group Report. Biol Blood Marrow Transplant. 2017; 23:870–881.
9 9. Vogelsang GB. How I treat chronic graft‐versus‐host disease. Blood. 2001; 97:1196–1201.
10 10. Lee SJ, Vogelsang G, Flowers MED. Chronic graft‐versus‐host disease. Biol Blood Marrow Transplant. 2003; 9:215–233.
11 11. Fuji S, Kapp M, Einsele H. Challenges to preventing infectious complications, decreasing re‐hospitalizations, and reducing cost burden in long‐term survivors after allogeneic hematopoietic stem cell transplantation. Semin Hematol. 2012; 49:10–14.
12 12. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009; 15:1143–1238.
13 13. Deeg HJ, Socie G. Malignancies after hematopoietic stem cell transplantation: many questions, some answers. Blood. 1998; 91:1833–1844.
14 14. Adès L, Guardiola P, Sociè G. Second malignancies after allogeneic hematopoietic stem cell transplantation: new insight and current problems. Blood Rev. 2002; 16:135–146.
15 15. Majhail NS. Long‐term complications after hematopoietic cell transplantation. Hematol Oncol Stem Cell Ther. 2017; 10:220–227.
16 16. Battiwalla M, Tichelli A, Majhail NS. Long‐term survivorship after hematopoietic cell transplantation: roadmap for research and care. Biol Blood Marrow Transplant. 2017; 23:184–192.
17 17. Socié G, Salooja N, Cohen A, et al. Nonmalignant late effects after allogeneic stem cell transplantation. Blood. 2003; 101:3373–3385.
18 18. Inamoto Y, Valdés‐Sanz N, Ogawa Y, et al. Ocular graft‐versus‐host disease after hematopoietic cell transplantation: Expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. Bone Marrow Transplant. 2019; 54:662–673.
19 19. Deeg HJ, Flournoy N, Sullivan KM, et al. Cataracts after total body irradiation and marrow transplantation: a sparing effect of dose fractionation. Int J Radiat Oncol Biol Phys. 1984; 10:957–964.
20 20. Tichelli A, Gratwohl A, Egger T, et al. Cataract formation after bone marrow transplantation. Ann Intern Med. 1993; 119:1175–1180.
21 21. Benyunes MC, Sullivan KM, Deeg HJ, et al. Cataracts after bone marrow transplantation: long‐term follow‐up of adults treated with fractionated total body irradiation. Int J Radiat Oncol Biol Phys. 1995; 32:661–670.
22 22. Belkacémi Y, Ozsahin M, Pène F, et al. Cataractogenesis after total body irradiation. Int J Radiat Oncol Biol Phys. 1996; 35:53–60.
23 23. Belkacemi Y, Labopin M, Vernant JP, et al. Cataracts after total body irradiation and bone marrow transplantation in patients with acute leukemia in complete remission: a study of the European Group for Blood and Marrow Transplantation. Int J Radiat Oncol Biol Phys. 1998; 41:659–668.
24 24. Socié G, Clift RA, Blaise D, et al. Busulfan plus cyclophosphamide compared with total‐body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long‐term follow‐up of 4 randomized studies. Blood. 2001; 98:3569–3574.
25 25. Gratwohl AA, Gratwhol AA, Moutsopoulos HM, et al. Sjögren‐type syndrome after allogeneic bone‐marrow transplantation. Ann Int Med. 1977; 87:703–706.
26 26. Mercier A, Devergie A, Arrago JP, et al. Systemic evaluation of Sjögren‐like syndrome after bone marrow transplantation in man. Transplantation. 1987; 43:677–679.
27 27. Jabs DA, Wingard J, Green WR, et al. The eye in bone marrow transplantation. III. Conjunctival graft‐vs‐host disease. Arch Ophthalmol. 1989; 107:1343–1348.
28 28. Tichelli A, Duell T, Weiss M, et al. Late‐onset keratoconjunctivitis sicca syndrome after bone marrow transplantation: incidence and risk factors. European Group or Blood and Marrow Transplantation (EBMT) Working Party on Late Effects. Bone Marrow Transplant. 1996; 17:1105–1111.
29 29. Bacigalupo A, Chien J, Barisione G, Pavletic S. Late pulmonary complications after allogeneic hematopoietic stem cell transplantation: diagnosis, monitoring, prevention, and treatment. Semin Hematol. 2012; 49:15–24.
30 30. Bondeelle L, Bergeron A. Managing pulmonary complications in allogeneic hematopoietic stem cell transplantation. Expert Rev Respir Med. 2019; 13:105–119.
31 31. Crawford SW, Fisher L. Predictive value of pulmonary function tests before marrow transplantation. Chest. 1992; 101:1257–1264.
32 32. Soubani AO, Miller KB, Hassoun PM. Pulmonary complications of bone marrow transplantation. Chest. 1996; 109:1066–1077.
33 33. Cerveri I, Fulgoni P, Giorgiani G, et al. Lung function abnormalities after bone marrow transplantation in children: has the trend recently changed? Chest, 120, 1900–1906.
34 34. Crawford SW, Pepe M, Lin D, et al. Abnormalities of pulmonary function tests after marrow transplantation predict nonrelapse mortality. Am J Respir Crit Care Med. 1995; 152:690–695.
35 35. Barker AF, Bergeron A, Rom WN, Hertz MI. Obliterative bronchiolitis. New Engl J Med. 2014; 370:1820–1828.
36 36. McClune B, Majhail NS, Flowers MED. Bone loss and avascular necrosis of bone after hematopoietic cell transplantation. Semin Hematol. 2012; 49:59–65.
37 37. Enright H, Haake R, Weisdorf D. Avascular necrosis of bone: a common serious complication of allogeneic bone marrow transplantation. Am J Med. 1990; 89:733–738.
38 38. Socié G, Sélimi F, Sedel L, et al. Avascular necrosis of bone after allogeneic bone marrow transplantation: clinical findings, incidence and risk factors. Br J Haematol 1994; 86:624–628.
39 39. Socié G, Cahn JY, Carmelo J, et al. Avascular necrosis of bone after allogeneic bone marrow transplantation: analysis of risk factors for 4388 patients by the Société Française de Greffe de Moëlle (SFGM). Br J Haematol. 1997; 97:865–870.
40 40. Fink JC, Leisenring WM, Sullivan KM, et al. Avascular necrosis following bone marrow transplantation: a case‐control study. Bone. 1998; 22:67–71.
41 41. Bizot P, Nizard R, Socié G, et al. Femoral head osteonecrosis after bone marrow transplantation. Clin Orthop Relat Res. 1998;( 357):127–134.
42 42. Campbell S, Sun C‐L, Kurian S, et al. Predictors of avascular necrosis of bone in long‐term survivors of hematopoietic cell transplantation. Cancer. 2009; 115:4127–4135.
43 43. Weilbaecher KN. Mechanisms of osteoporosis after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2000; 6:165–174.
44 44. Schimmer AD, Minden MD, Keating A. Osteoporosis after blood and marrow transplantation: